[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hpv-human-papillomavirus-associated\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hpv-human-papillomavirus-associated":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,92,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100645761","phase-2-treatment-of-recurrent-genital-warts-by-combination-of-co2-laser-and-geniwa-gel-100645761",false,"NCT07698886","Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel","Inclusion Criteria:\n\n1. 18 years of age or older.\n2. Able to read and understand the Patient Information Sheet and the Informed Consent form.\n3. Acceptance in the participation of the essay and signature of the Informed Consent form.\n4. Diagnosis of genital and anal warts with clear clinical manifestations.\n5. Have undergone at least 2 laser treatments and have experienced recurrence in any location.\n6. At least four or more lesions, or a lesion area of at least 0.5 cm2.\n\nExclusion Criteria:\n\n1. Concomitant sexually transmitted infections such as gonorrhea, syphilis, genital herpes, etc., that have not been cured.\n2. Ulceration or suspected malignant transformation of the lesions.\n3. Local infections.\n4. Pregnant women.\n5. Allergies to any component of alpha-lactalbumin-oleic acid gel.","ALL","18 Years",{"count":18,"type":19},70,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","Phase II, a randomized, double-blind, placebo-controlled clinical trial to evaluate the effectiveness and recurrence of genital warts by combination of CO2 laser and Geniwa gel compared to laser CO2 combined with gel placebo. The clinical trial is conducted at National Dermatology Hospital, Hanoi, Vietnam.",[25,26],"HPV (Human Papillomavirus)-Associated","Genital Warts",[28,29],"HPV","Genital warts","RECRUITING","2026-08-19",{"date":33,"type":34},"2026-08-21","ACTUAL",{"date":36,"type":34},"2026-07-16",{"date":38,"type":19},"2027-09-15",{"name":40,"class":41},"KTH Biopharma","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":55,"briefSummary":57,"conditions":58,"keywords":68,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100614592","evaluation-of-the-q-pad-hrhpv-test-system-for-identifying-precancer-100614592","NCT07281599","Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer","EQUIP","Inclusion Criteria:\n\n* You are 25 years old or older and have an intact cervix.\n* You were referred for a colposcopy after an abnormal Pap or HPV screen.\n* Your periods come regularly-about every 21-35 days.\n* You own a smartphone, have an email address, and can read the Qvin app instructions in English.\n* You are willing to sign the consent form (electronically).\n* You agree to use a condom for any vaginal intercourse or shared penetrative toy use from Q-Pad collection until the colposcopy visit if engaging with a new sexual partner during this period.\n\nExclusion Criteria:\n\n* You are pregnant or think you might be.\n* You are unwilling or unable to use the two Q-Pads and mail them back (mailing costs are covered).\n* You had treatment for cervical pre-cancer (CIN2+)-such as LEEP, cone, or ablation-within the last 12 months.\n* You have already joined this study or are in another cervical-screening \u002F HPV study right now.",true,"FEMALE","25 Years",{"count":54,"type":19},450,[56],"NA","The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing.\n\nThe same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care. By comparing hrHPV results from menstrual samples with results from cervical samples and biopsy findings, the study will evaluate how well the Q-Pad hrHPV Test System detects cervical precancer and will also assess how easy and acceptable it is for participants to use this at-home collection method.",[59,60,61,62,63,64,28,25,65,66,67],"HPV Infection","HPV 16 Infection","High Risk HPV","Cervical Cancer Screening","Cervical Cancer Cin Grade","Cervical Cancer (Early Detection)","HPV DNA","HPV Infections","Screening Test",[69,70,71,72,73,74,75,76,77,78,28,79,80,81],"Q-Pad","Self-sampling","Self-collection","self-collect","cervical cancer screening","menstural blood","Sexually Transmitted Diseases, Viral","Sexually Transmitted Diseases","Genital Diseases","Papillomavirus Infections","high risk HPV","pap smear","at-home collection","2026-07-22",{"date":84,"type":34},"2026-07-24",{"date":86,"type":34},"2025-12-01",{"date":88,"type":19},"2027-03",{"name":90,"class":41},"Qurasense",3,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":20,"phases":102,"briefSummary":103,"conditions":104,"keywords":108,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":125},"100616488","multicenter-prospective-non-randomized-controlled-study-of-ella-photodynamic-therapy-for-cervical-hsilcin2-100616488","NCT07306260","Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical HSIL\u002FCIN2","PDT for CIN2","Inclusion Criteria:\n\n1. Female, 25-60 years, understands study procedures and consents to participate;\n2. Colposcopy-guided cervical biopsy within 3 months showing HSIL\u002FCIN2;\n3. Provides written informed consent.\n\nExclusion Criteria:\n\n1. Cytology showing ASC-H, HSIL, AGC, or AIS; or evidence of malignant cells on cytology\u002Fhistology, or suspicion of malignancy or invasive cancer;\n2. Colposcopy findings suggestive of invasive cancer or lesion extension to the vaginal wall;\n3. Severe pelvic, cervical, or other gynecological inflammatory conditions identified clinically;\n4. Undiagnosed vaginal bleeding;\n5. Active allergic disease, porphyria, or history of allergy to the study drug or structurally similar agents;\n6. Severe cardiovascular, neurological, psychiatric, endocrine, hepatic, or hematologic disorders; known immunodeficiency; long-term glucocorticoid or immunosuppressant use; active autoimmune disease; or other malignancies;\n7. Pregnant or breastfeeding women;\n8. History of hysterectomy, cervical cancer treatment, or cervical excision\u002Fablation within 6 months (e.g., conization, LEEP, laser);\n9. Use of interferon or antiviral therapy within 3 months;\n10. Any other condition deemed unsuitable for participation by the investigator.","65 Years",{"count":101,"type":19},560,[56],"This study evaluates the efficacy and safety of ALA-PDT versus LEEP in treating cervical HSIL\u002FCIN2, aiming to demonstrate non-inferiority in clinical efficacy.",[105,106,25,107],"HSIL, High Grade Squamous Intraepithelial Lesion","CIN 2","Photodynamic Therapy (PDT)",[109,110,111,112,113],"photodynamic therapy","High Grade Squamous Intraepithelial Lesion","human papillomavirus","loop electrosurgical excision procedure","efficacy","NOT_YET_RECRUITING","2025-12-14",{"date":117,"type":34},"2025-12-29",{"date":119,"type":19},"2026-01",{"date":121,"type":19},"2027-12",{"name":123,"class":124},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",5,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":20,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":125},"100577062","phase-2-vaccination-against-human-papillomavirus-hpv-after-allogeneic-stem-cell-transplantation-100577062","NCT06793410","Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation","Vaccination Against Human Papillomavirus (HPV) in Women and Men After Stem Cell Transplantation","Inclusion Criteria:\n\n* Recipient of AlloSCT from related or unrelated donor.\n* Adults (men and women) ≥18 years up to and including 45 years of age for vaccination.\n* Patients can be included regardless of prior HPV vaccination prior to transplantation\n\nExclusion Criteria:\n\n* Severe thrombocytopenia (under 50 x 10\\^9) not allowing intramuscular injection\n* Severe acute GvHD grade III-IV.\n* Extensive chronic GvHD requiring treatment with prednisone doses above 0.7 mg\u002Fkg\u002Fday plus at least two other systemic treatments against GvHD (for example ruxolitinib or photopheresis).\n* Prednisone doses above 1mg\u002Fkg\u002Fday at study start.\n* Treatment with rituximab 6 months before start of vaccination. Doses given later (unusual) do not require exclusion.\n* Treatment within 3 months before start of vaccination with iv or sc immunoglobulin.\n* Pregnancy, pregnancy desire or active pregnancy planning during time vaccine is given and up to three months after last vaccine dose.\n* Treatment with blood thinning medication contraindicating intramuscular injection\n* Allergy against Gardasil 9","45 Years",{"count":135,"type":19},100,[22],"Patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases. For several reasons, these patients have a long-term immune deficiency due to the transplant itself (lack of immune reconstitution) and due to possible complications, primarily GvHD and its treatment. The risk of secondary malignancy in the long-term following an allogeneic bone marrow transplant is greatly increased, and secondary cancer cases account for a significant proportion of late deaths in both women and men after transplantation. Some of these secondary cancers are associated with HPV. The risk of cervical cancer has been reported to be 13 times increased compared to a healthy population.\n\nTherefore in this trial, the aim is to study immune response (antigen-specific antibody response) after vaccination with 9-valent HPV vaccine (Gardasil 9®) in adult women and men (up to and including 45 years of age) who have undergone allogeneic stem cell transplantation. In this trial, the sponsor will compare \"early\" (start 9 months after tx) with \"late\" (start 15 months after tx) vaccination.",[139,25,140,141,142],"Recipients of Allogeneic Stem Cell Transplantation","Acute Myeloid Leukaemia","Myelodysplastic Syndrome","Diffuse Large B Cell Lymphoma (DLBCL)","2025-06-04",{"date":145,"type":34},"2025-06-05",{"date":147,"type":34},"2025-05-12",{"date":149,"type":19},"2029-10-31",{"name":151,"class":152},"Vastra Gotaland Region","OTHER_GOV"]